VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
GRDN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
GRDNGuardian Pharmacy Services, Inc.
$46.94$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksGRDNBalance Sheet

Guardian Pharmacy Services, Inc. (GRDN) Balance Sheet

8Y historyFree accessUpdated daily

Total debt has stabilized near $35.6M while the debt-to-equity ratio fell from 1.33 to 0.13 and cash rose to $119.7M with a current ratio of 1.65, pointing to a strengthened capital structure built largely through retained earnings.

Income StatementBalance SheetCash FlowRatios

GRDN Balance Sheet

Annual statement

GRDN Balance Sheet

Guardian Pharmacy Services, Inc. (GRDN) balance sheet — 8-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Total Current Assets294.82M221.63M151.99M129.6M120M111.87M93.82M90.08M81.23M
Cash & Short-Term Investments119.66M65.62M4.66M752K607K15.01M6.45M275K2.25M
Cash Only119.66M65.62M4.66M752K607K15.01M6.45M275K2.25M
Short-Term Investments000000000
Accounts Receivable107.68M101.61M97.15M77.26M67.83M55.25M45.78M54.21M47.66M
Days Sales Outstanding26.625.628.8726.9627.2425.4622.728.3428.97
Inventory57.05M43.36M40.55M36.73M41.44M33.09M31.93M30.94M27.54M
Days Inventory Outstanding15.9913.5715.041620.9219.1519.7920.3521.06
Other Current Assets10.43M11.04M9.62M14.86M10.12M8.52M2.89M4.66M3.78M
Total Non-Current Assets196.96M191.02M168.82M141.56M136.12M123.98M124.05M106.43M100.58M
Property, Plant & Equipment90.2M90.17M78.96M73.18M65.19M51.72M51.98M35.41M27.98M
Fixed Asset Turnover16.18x16.07x15.56x14.30x13.94x15.31x14.16x19.72x21.46x
Goodwill81.95M79.74M69.3M56.05M56.05M54.63M52.45M46.33M47.82M
Intangible Assets20.84M18.48M14.91M11.98M14.44M17.09M19.11M20.69M23.82M
Long-Term Investments000000000
Other Non-Current Assets1.35M436K383K358K435K529K505K4.01M953K
Total Assets491.78M412.66M320.81M271.17M256.11M235.85M217.87M196.51M181.81M
Asset Turnover3.28x3.51x3.83x3.86x3.55x3.36x3.38x3.55x3.30x
Asset Growth %107.03%28.63%18.31%5.88%8.59%8.25%10.87%8.09%-
Total Current Liabilities179.09M160.7M144.12M138.01M112M111.54M86.35M90.19M65.27M
Accounts Payable126.31M116.21M102.42M85.6M78.1M64.62M53.41M54.93M47.53M
Days Payables Outstanding37.0936.3637.9937.2939.4337.3933.136.1436.34
Short-Term Debt00012.98M7.96M3.71M3.63M17.04M2.64M
Deferred Revenue (Current)000000000
Other Current Liabilities25.28M37.35M34.87M12.33M3.62M20.42M09.94M7.68M
Current Ratio1.65x1.38x1.05x0.94x1.07x1.00x1.09x1.00x1.24x
Quick Ratio1.33x1.11x0.77x0.67x0.70x0.71x0.72x0.66x0.82x
Cash Conversion Cycle5.52.815.925.668.737.219.3912.5513.69
Total Non-Current Liabilities32.97M34.03M26.71M73.29M68.18M70.99M64.44M49.28M48.53M
Long-Term Debt00018.99M22.97M26.99M30.74M33.66M36.37M
Capital Lease Obligations115.48M29.99M23.3M27.04M23.67M16.12M15.54M3.59M2.35M
Deferred Tax Liabilities000000000
Other Non-Current Liabilities5M4.04M3.42M27.26M21.54M27.88M18.16M12.03M9.81M
Total Liabilities212.06M194.73M170.83M211.31M180.18M182.53M150.8M139.47M113.8M
Total Debt35.59M37.14M30.13M69.15M62.98M55.04M58.84M57.12M43.71M
Net Debt-84.06M-28.48M25.47M68.4M62.38M40.03M52.39M56.84M41.46M
Debt / Equity0.13x0.17x0.20x1.16x0.83x1.03x0.88x2.06x0.64x
Debt / EBITDA0.29x0.33x-1.17x0.92x1.18x1.19x1.14x1.12x
Net Debt / EBITDA-0.68x-0.26x-1.16x0.91x0.86x1.06x1.14x1.06x
Interest Coverage163.29x111.41x-19.28x14.19x26.78x18.30x14.76x14.94x13.25x
Total Equity279.72M217.92M149.98M59.86M75.93M53.32M67.07M27.72M68.01M
Equity Growth %174.19%45.31%150.55%-21.16%42.41%-20.5%141.97%-59.24%-
Book Value per Share4.383.442.420.981.250.881.100.461.12
Total Shareholders' Equity267.24M205.76M142.67M28.21M42.73M23.93M38.48M034.03M
Common Stock63K63K63K28.21M42.73M24.11M39.15M29.95M34.03M
Retained Earnings120.19M66.34M17.12M000000
Treasury Stock000000000
Accumulated OCI00000-185K-676K-630K-386K
Minority Interest12.48M12.16M7.3M31.65M33.2M29.39M28.59M27.72M25.86M

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowImproving
Top Statement Risk

Thin margins amid pricing pressure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Equity Base Rebuilt Through Retained Earnings

Based on reported balance sheet figures, GRDN's equity rose from $17.9M in Q2 2024 to $267.2M in Q3 2026, with retained earnings climbing from zero to $120.2M, indicating a balance sheet strengthening through internal profit generation rather than external capital.

The transition from a near-zero equity base to a $267.2M position within roughly two years suggests the earnings base has been retained rather than distributed in recent periods. Total assets growing from $305.1M to $491.8M alongside a sharp rise in cash to $119.7M points to a company that is accumulating liquidity. This pattern warrants monitoring for whether retained cash is deployed productively into acquisitions or organic growth, given that the recent EPS miss may slow the pace of retained earnings accumulation.

Leverage Reduced to Minimal Levels

According to reported figures, GRDN's debt-to-equity ratio fell from 1.33 in Q2 2024 to 0.13 in Q3 2026, with total debt stabilizing near $35.6M, suggesting a deliberate deleveraging rather than a refinancing-driven improvement.

Total debt has held in a narrow $33.7M to $37.1M range since early 2025 while equity expanded, which mechanically compressed the leverage ratio. The earlier debt spike to roughly $76.0M appears to have been retired or restructured, though the reported data does not disclose the specific repayment mechanism. Low leverage preserves financial flexibility for acquisitions and absorbs margin shocks, though the reported figures do not indicate the terms, maturity profile, or covenants attached to the remaining obligations.

Cash Buffer Strengthening Against Working Capital Swings

As reported in financial statements, GRDN's cash rose from $4.7M in Q4 2024 to $119.7M in Q3 2026, while the current ratio improved from 1.05 to 1.65, indicating a meaningfully larger buffer against working capital volatility.

The current ratio of 1.65 and cash of $119.7M provide a substantive cushion relative to a business with a 19.5% gross margin and quarterly operating income near $25M. Given that prior cash flow analysis showed working capital swings of roughly $16M in either direction, this liquidity position appears adequate to absorb a single adverse quarter. The cash build appears partly driven by operating cash generation, though the sustainability of this buffer depends on whether working capital reversals recur.

Asset-Light Model With Growing Goodwill Exposure

Reported figures show goodwill increasing from $66.4M to $82.0M and net PP&E holding near $90M, suggesting an asset base that is increasingly weighted toward acquired intangibles rather than physical capital.

Goodwill now represents a meaningful share of total assets of $491.8M, and its growth tracks the bolt-on acquisition activity noted in prior cash flow findings. Net PP&E at roughly $90M relative to a business of this revenue scale is consistent with a capital-light pharmacy services model. If acquired contracts underperform, goodwill impairment could erode equity, though the reported data does not indicate any impairment charges or testing outcomes.

Cash Build Masks Thin Earnings Cushion

Based on reported figures, the rise in cash to $119.7M coincides with a net margin of 5.0% and an operating margin of 6.8%, so the apparent strength of the balance sheet may be more dependent on working capital timing than on sustained earnings power.

A strong cash position paired with thin profitability can overstate financial resilience if a portion of the cash build reflects timing of payables or receivables rather than durable earnings. The Q3 2026 EPS shortfall against consensus reinforces the possibility that margin pressure could erode retained earnings growth faster than the balance sheet currently reflects. Investors should monitor whether future cash accumulation tracks net income or diverges from it.

GRDN — Frequently Asked Questions

Quick answers to the most common questions about buying GRDN stock.

What are the total assets of Guardian Pharmacy Services, Inc. (GRDN)?

As of 2025, Guardian Pharmacy Services, Inc. (GRDN) had total assets of $412.7M including $221.6M in current assets.

How much debt does Guardian Pharmacy Services, Inc. (GRDN) have?

Guardian Pharmacy Services, Inc. (GRDN) carries total debt of $37.1M, offset by $65.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Guardian Pharmacy Services, Inc.?

Guardian Pharmacy Services, Inc. (GRDN) has total shareholders' equity (book value) of $205.8M ($3.44 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Guardian Pharmacy Services, Inc.'s current ratio and liquidity?

Guardian Pharmacy Services, Inc. (GRDN) reported a current ratio of 1.38x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.